Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma. METHODS: In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (453 patients). The patients were treated for a period of up to 1 year or until disease recurrence, a report of unacceptable toxic effects, or withdrawal of consent. The primary end point was recurrence-free survival in the intention-to-treat population. RESULTS: At a minimum follow-up of 18 months, the 12-month rate of recurrence-free survival was 70.5% (95% confidence interval [CI], 66.1 to 74.5) in the nivolumab group and 60.8% (95% CI, 56.0 to 65.2) in the ipilimumab group (hazard ratio for disease recurrence or death, 0.65; 97.56% CI, 0.51 to 0.83; P<0.001). Treatment-related grade 3 or 4 adverse events were reported in 14.4% of the patients in the nivolumab group and in 45.9% of those in the ipilimumab group; treatment was discontinued because of any adverse event in 9.7% and 42.6% of the patients, respectively. Two deaths (0.4%) related to toxic effects were reported in the ipilimumab group more than 100 days after treatment. CONCLUSIONS: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906 ; Eudra-CT number, 2014-002351-26 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [191]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Research works printed but not linked: 1
- Tarhini AA, 2017, J Clin Oncol, 35
Cited by
Items 601–700 of 1,000
Neoadjuvant therapy of locally/regionally advanced melanoma
Khunger, A., Buchwald, Z. S., Lowe, M., Khan, M. K., Delman, K. A., & Tarhini, A. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919866959 · Cited by 29
The Future of Immunotherapy in the Treatment of Cancer
Kottschade, L. A. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.08.013 · Cited by 29
Primary Cutaneous Melanoma—Management in 2024
Dixon, A. J., Sladden, M. J., Zouboulis, C. C., Popescu, C. M., Nirenberg, A., Steinman, H. K., Longo, C., Dixon, Z. L., & Thomas, J. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061607 · Cited by 29
“This review of recent developments in melanoma management is based on the selection of publications since 2017 that the authors considered pertinent.”
BackgroundRational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)
Monsen, P. J., Bommi, P. V., Grigorescu, A. A., Lauing, K. L., Mao, Y., Berardi, P., Zhai, L., Ojo, O., Penco-Campillo, M., Koch, T., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00026 · Cited by 32
T Lymphocyte–Based Cancer Immunotherapeutics
Borrie, A. E., & Vareki, S. M. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.05.010 · Cited by 29
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
Fenton, S. E., Sosman, J. A., & Chandra, S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.28 · Cited by 37
Pal, S. K., McDermott, D. F., Atkins, M. B., Escudier, B. J., Rini, B. I., Motzer, R. J., Fong, L. H., Joseph, R. W., Oudard, S. M., Ravaud, A., et al. (2020) · British Journal of Urology · doi:10.1111/bju.15058 · Cited by 28
Self-citationMoore, M. R., Friesner, I. D., Rizk, E. M., Fullerton, B. T., Mondal, M., Trager, M. H., Mendelson, K., Chikeka, I., Kurç, T., Gupta, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-82305-1 · Cited by 29
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
Najjar, Y. G., McCurry, D., Huang, L., Lin, Y., Zang, Y., Davar, D., Karunamurthy, A. D., Drabick, J. J., Neves, R. I., Butterfield, L. H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4301 · Cited by 29
Lodde, G. C., Forschner, A., Hassel, J. C., Wulfken, L. M., Meier, F. E., Mohr, P., Kähler, K. C., Schilling, B., Loquai, C., Berking, C., et al. (2021) · Cancers · doi:10.3390/cancers13102319 · Cited by 29
“7% of nivolumab- or pembrolizumab-treated patients [16,17].”
BackgroundThe role of immunotherapy and molecular‑targeted therapy in the treatment of melanoma (Review)
Stachyra, P., Ciesielka, M., Janiszewski, M., & Grzybowska‐Szatkowska, L. (2021) · Oncology Reports · doi:10.3892/or.2021.8109 · Cited by 29
Cheraghlou, S., Ugwu, N., & Girardi, M. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.4812 · Cited by 28
Dimitriou, F., Hauschild, A., Mehnert, J. M., & Long, G. V. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351123 · Cited by 30
Self-citationResearch progress on immunotherapy in triple‑negative breast cancer (Review)
Zhang, X., Ge, X., Jiang, T., Yang, R., & Li, S. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5385 · Cited by 29
“4%) related to toxic effects were reported in the ipilimumab group (89).”
Bredin, P., & Naidoo, J. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10039-1 · Cited by 29
Vaddi, P. K., Osborne, D. G., Nicklawsky, A., Williams, N. K., Menon, D. R., Smith, D. E., Mayer, J., Reid, A. L., Domenico, J. M., Nguyen, G. H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1173035 · Cited by 28
Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma
Giles, K. M., Rosenbaum, B. E., Berger, M., Izsak, A., Li, Y., Bochaca, I. I., de Miera, E. V., Wang, J., Darvishian, F., Zhong, J., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.07.031 · Cited by 32
“Adjuvant anti-PD-1 therapy delays recurrence in resected stage III/IV melanoma (Weber et al., 2017); thus monitoring tumor PTEN expression may guide patient selection for adjuvant immunotherapy.”
BackgroundHamuro, L., Statkevich, P., Bello, A., Roy, A., & Bajaj, G. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1502 · Cited by 27
“In this randomized study, patients who received nivolumab in the adjuvant setting had a 35% reduction in the risk of disease recurrence or death compared with those who received ipilimumab, the standard of care in the United States.(5) In the current study, nivolumab population pharmacokinetic (PopPK) analyses were co…”
BackgroundMethodInfluentialTrager, M. H., Coley, S. M., Dube, G. K., Khan, S. A., Ingham, M. A., Samie, F. H., Geskin, L. J., McDonnell, D. E., Brouder, D., Saenger, Y. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000908 · Cited by 29
Research Interest and Public Interest in Melanoma: A Bibliometric and Google Trends Analysis
Zhang, H., Wang, Y., Zheng, Q., Tang, K., Fang, R., Wang, Y., & Sun, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.629687 · Cited by 28
Management of cutaneous melanoma: radiologists challenging and risk assessment
Granata, V., Simonetti, I., Fusco, R., Setola, S. V., Izzo, F., Scarpato, L., Vanella, V., Festino, L., Simeone, E., Ascierto, P. A., et al. (2022) · La radiologia medica · doi:10.1007/s11547-022-01522-4 · Cited by 28
Self-citationImmunotherapy and delivery systems for melanoma
Liu, H., Gou, X., Tan, Y., Fan, Q., & Chen, J. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2394252 · Cited by 30
“39 In a Phase III clinical trial, ipilimumab was the first drug to improve overall survival in patients with advanced melanoma.”
BackgroundGenta, S., Araújo, D. V., Hueniken, K., Pipinikas, C., Ventura, R., Rojas, P., Jones, G., Butler, M. O., Saibil, S. D., Yu, C., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103978 · Cited by 30
Self-citationFujisawa, Y., Yoshikawa, S., Minagawa, A., Takenouchi, T., Yokota, K., Uchi, H., Noma, N., Nakamura, Y., Asai, J., Kato, J., et al. (2019) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.04.003 · Cited by 26
Self-citationChen, S., Guo, W., Liu, X., Sun, P., Wang, Y., Ding, C., Meng, L., & Zhang, A. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.037 · Cited by 26
Evolution of Molecular Targets in Melanoma Treatment
Tran, K. B., Buchanan, C. M., & Shepherd, P. R. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200130091318 · Cited by 35
Severe steroid refractory gastritis induced by Nivolumab: A case report
Vindum, H. H., Agnholt, J. S., Nielsen, A. W. M., Nielsen, M. B., & Schmidt, H. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i16.1971 · Cited by 27
Kardos, G. R., Gowda, R., Dinavahi, S. S., Kimball, S. R., & Robertson, G. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00834 · Cited by 26
Optimal systemic therapy for high-risk resectable melanoma
Eggermont, A. M. M., Hamid, O., Long, G. V., & Luke, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00630-4 · Cited by 28
Self-citationGorris, M. A. J., van der Woude, L. L., Kroeze, L. I., Bol, K. F., Verrijp, K. N., Amir, A. L., Meek, J., Textor, J. C., Figdor, C. G., & de Vries, I. J. M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004329 · Cited by 36
Fastner, S. L., Hieken, T. J., McWilliams, R. R., & Hyngstrom, J. R. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27381 · Cited by 26
“6 | ADJUVANT SYSTEMIC THERAPY Anti PD‐1 monotherapy(51,52) and combination BRAF and MEK inhibitor therapy(38) have dramatically improved outcomes for patients with stage IV melanoma, and in 2018, single agent anti PD‐1 and BRAF/MEK systemic therapy gained FDA approval for treatment of resected stage III patients.(39,4…”
BackgroundAdvancing Cancer Research: Current Knowledge on Cutaneous Neoplasia
Stătescu, L., Trandafir, L. M., Țarcă, E., Moscalu, M., Leon, M. M., Butnariu, L. I., Trandafirescu, M. F., Tîrnovanu, M. C., Heredea, R., Pătrașcu, A. V., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311176 · Cited by 30
“It shows fewer grade 3/4 adverse events compared with toxic high dose ipilimumab [17].”
BackgroundJacques, S. K., McKeown, J., Grover, P., Johnson, D. B., Zaremba, A., Dimitriou, F., Weiser, R., Farid, M., Namikawa, K., Sullivan, R. J., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113563 · Cited by 26
Self-citationSentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma
Masoud, S. J., Perone, J. A., Farrow, N. E., Mosca, P. J., Tyler, D. S., & Beasley, G. M. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0575-4 · Cited by 31
Baltussen, J. C., Welters, M. J. P., Verdegaal, E. M. E., Kapiteijn, E., Schrader, A. M. R., Slingerland, M., Liefers, G., van der Burg, S. H., Portielje, J. E. A., & de Glas, N. A. (2021) · Cancers · doi:10.3390/cancers13246366 · Cited by 34
Rutkowski, P. L., Wysocki, P. J., Nasierowska-Guttmejer, A. M., Jeziorski, A., Wysocki, W. M., Kalinka‐Warzocha, E., Świtaj, T., Kozak, K., Kamińska‐Winciorek, G., Czarnecka, A. M., et al. (2020) · Oncology in Clinical Practice · doi:10.5603/ocp.2020.0021 · Cited by 28
Self-citationMultidisciplinary approach and treatment of acral and mucosal melanoma
Fortuna, A., & Amaral, T. M. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1340408 · Cited by 27
“A total of 33 patients diagnosed with AM and 29 patients with MM were enrolled, but in the subgroup analysis, the magnitude of the bene fi t of the different treatments for each melanoma subtype was inconclusive due to the small number of patients enrolled in each subgroup (73).”
BackgroundManagement of in‐transit melanoma metastases: a review
Tie, E. N., Henderson, M. A., & Gyorki, D. E. (2018) · ANZ Journal of Surgery · doi:10.1111/ans.14921 · Cited by 25
“At 12 months the rate of recurrence-free survival for in stage IIIB/C patients was 71% in the ipilimumab group and 61% nivolumab group.(10) The proportion of patients with ITM was not recorded.”
BackgroundMethodBeielstein, A. C., & Pallasch, C. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174158 · Cited by 26
Chai, Q., Du, J., Zhu, J., & Wu, B. Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01260 · Cited by 25
“16 (Weber et al., 2017) Checkmate238 III Doubleblind 906 19.”
BackgroundNeoadjuvant Immunotherapy for Locally Advanced Melanoma
Pelster, M. S., & Amaria, R. N. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0700-z · Cited by 29
Adjuvant immunotherapy: the sting in the tail
Higham, C., Chatzimavridou-Grigoriadou, V., Fitzgerald, C. T., Trainer, P. J., Eggermont, A. M. M., & Lorigan, P. C. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.016 · Cited by 25
Anota, A., Pozet, A., Lemasson, H., Cotté, F.-E., Falcoz, A., Eberst, G., Mouillet, G., Guerzider, S., Charton, É., & Westeel, V. (2021) · Quality of Life Research · doi:10.1007/s11136-021-02945-8 · Cited by 29
Moncrieff, M. D., Pywell, S., Snelling, A. P., Gray, M., Newman, D. R., Beadsmoore, C. J., Pawaroo, D., & Heaton, M. J. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10911-4 · Cited by 25
“In addition, maturing data from large phase III clinical trials are suggesting a long-term survival benefit from adjuvant systemic therapy.(19,20) Accordingly, the accurate identification of SLNs has taken on an additional significance in the past few years.”
BackgroundZaremba, A., Kramer, R., DeTemple, V. K., Bertram, S., Salzmann, M., Gesierich, A., Reinhardt, L., Baroudjian, B., Sachse, M., Mechtersheimer, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.765608 · Cited by 27
Self-citationFelip, E., Moreno, V., Morgensztern, D., Curigliano, G., Rutkowski, P. L., Trigo, J. M., Calvo, A., Kowalski, D. M., Cortinovis, D. L., Plummer, R., et al. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04414-6 · Cited by 26
Self-citationStahlie, E. H. A., Mulder, E. E. A. P., Reijers, S. J. M., Balduzzi, S., Zuur, C. L., Klop, W. M. C., van der Hiel, B., van de Wiel, B. A., Wouters, M. W. J. M., Schrage, Y. M., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103705 · Cited by 25
ICIs-Related Cardiotoxicity in Different Types of Cancer
Dong, M., Yu, T., Zhang, Z., Zhang, J., Wang, R., Tse, G., Liu, T., & Zhong, L. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9070203 · Cited by 26
“, 2017 [27] Prospective study III 906 (453 vs.”
Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis
Liu, M., Cheng, X., Ni, R., Zheng, B., Huang, S., & Yang, J. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1006860 · Cited by 27
“In contrast, PD-1 or PD-L1 caused high-grade adverse events in only 10%-15% of patients (23, 24).”
BackgroundSystemic adjuvant therapy for high-risk cutaneous melanoma
Kobeissi, I., & Tarhini, A. A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221134087 · Cited by 26
“CheckMate-238, for example, compared nivolumab to ipilimumab and found that nivolumab improved RFS but not OS (20).”
BackgroundNail Apparatus Melanoma: Current Management and Future Perspectives
Ito, T., Hashimoto, H., Kaku‐Ito, Y., Tanaka, Y., & Nakahara, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062203 · Cited by 26
Yu, C., Hsieh, K., Cherry, D. R., Nehlsen, A. D., Salgado, L. R., Lazarev, S., & Sindhu, K. K. (2023) · Biology · doi:10.3390/biology12121528 · Cited by 29
“…of immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy to glioblastoma, as these modalities have yielded remarkable improvements in the management of several previously intractable tumors, including melanoma [5–7] and non-small-cell lung cancer (NSCLC) [8].”
BackgroundIsaksson, K., Katsarelias, D., Mikiver, R., Carneiro, A., Ny, L., & Bagge, R. O. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07448-y · Cited by 26
Approaches to High-Risk Resected Stage II and III Melanoma
Yushak, M. L., Mehnert, J. M., Luke, J. J., & Poklepovic, A. S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239283 · Cited by 26
Yang, L., Dong, X., Xing, X., Cui, X., Li, L., & Zhang, L. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i11.1346 · Cited by 26
Adam, T., Becker, T. M., Chua, W. M., Bray, V., & Roberts, T. L. (2021) · Cancers · doi:10.3390/cancers13020277 · Cited by 27
Kalsi, S., Galenkamp, A. L., Singh, R., Khosla, A. A., McGranaghan, P., & Cintolo-Gonzalez, J. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01611-9 · Cited by 27
Barroso‐Sousa, R., & Ott, P. A. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0738-2 · Cited by 25
Ellis, R., Tang, D. Y. L., Nasr, B. B., Greenwood, A., McConnell, A., Anagnostou, M., Elias, M. L., Verykiou, S., Bajwa, D. S., Ewen, T., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18086 · Cited by 25
The Evolution of Adjuvant Therapy for Melanoma
Cohen, J. V., & Buchbinder, E. I. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0858-3 · Cited by 28
Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects
Pilla, L., Alberti, A., di Mauro, P., Gemelli, M. T., Cogliati, V., Cazzaniga, M. E., Bidoli, P., & Maccalli, C. (2020) · Cancers · doi:10.3390/cancers12113456 · Cited by 31
“Indeed, the results of 2 different studies in the adjuvant setting, one comparing nivolumab to ipilimumab and pembrolizumab to placebo, respectively, showed that recurrence-free survival was longer in patients with PD-L1 positive tumors, irrespectively from the treatment [4,84].”
BackgroundResultBagge, R. O., Ny, L., Ascierto, P. A., Hodi, F. S., Larkin, J., Robert, C., Schachter, J., Weber, J. S., Long, G. V., & van Akkooi, A. C. J. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000719 · Cited by 25
Self-citationLauwyck, J., Beckwée, A., Santens, A., Schwarze, J. K., Awada, G., Vandersleyen, V., Aspeslagh, S., & Neyns, B. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000748 · Cited by 27
Temperley, H. C., O’Sullivan, N. J., Keyes, A. M., Kavanagh, D. O., Larkin, J. O., Mehigan, B. J., McCormick, P. H., & Kelly, M. E. (2022) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-022-02715-1 · Cited by 24
Self-citationLocal γδ T cells: translating promise to practice in cancer immunotherapy
Zlatareva, I., & Wu, Y. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02303-0 · Cited by 27
“Of the many CPIs currently available, anti-PD-(L)1 therapies have consistently proven to be the most efficacious [8, 13, 151] and now comprise the backbone of a large proportion of immunotherapy combination trials, including those involving novel agents [152].”
Mangla, A., Lee, C., Mirsky, M. M., Wang, M., Rothermel, L. D., Hoehn, R. S., Bordeaux, J. S., Carroll, B. T., Theuner, J., Li, S., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.7333 · Cited by 26
Neoadjuvant therapy in melanoma: the next step?
Ascierto, P. A., & Eggermont, A. M. M. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30016-0 · Cited by 24
Self-citationThe Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies
Keung, E. Z.-Y., & Wargo, J. A. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.008 · Cited by 24
Johnson, D. B., Taylor, K. B., Cohen, J. V., Ayoubi, N., Haugh, A. M., Wang, D. Y., Schlick, B. D., Voorhees, A. L., Gage, K. L., Fintelmann, F. J., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0717 · Cited by 24
“These agents are now approved as adjuvant therapy for high-risk melanoma following surgical resection and as maintenance therapy for stage III non–small cell lung cancer (NSCLC) following definitive chemoradiation (3, 4).”
BackgroundInfluentialWeilandt, J., Diehl, K., Schaarschmidt, M., Kiecker, F., Sasama, B., Pronk, M., Ohletz, J., Könnecke, A., Müller, V. A., Utikal, J. S., et al. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3422 · Cited by 26
Zhou, L., Yang, S., Li, Y., Xue, C., & Wan, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448728 · Cited by 25
Sugiyama, K., Gordon, A., Popat, S., Okines, A. F. C., Larkin, J., & Chau, I. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104122 · Cited by 30
“10,14,70 Following pioneering trials that demonstrated the ef fi cacy and broader T-cell response in the tumour microenvironment through neoadjuvant pem-brolizumab 71 or ipilimumab and nivolumab, 72 neoadjuvant ICI is currently under active investigation.”
Self-citationLong, G. V., Nair, N., Marbach, D., Scolyer, R. A., Wilson, S., Cotting, D., Städler, N., Amaria, R. N., Ascierto, P. A., Tarhini, A. A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03967-2 · Cited by 32
“…adjuvant anti-programmed cell death protein 1 (PD-1) therapy or BRAF -targeted therapy for patients treated with upfront resection, or neoadjuvant nivolumab plus ipilimumab followed by adjuvant therapy based on pathological response and BRAF status, or neoadjuvant plus adjuvant pembrolizumab 1–5 .”
Self-citationClinical development of cancer vaccines
Haanen, J. B. A. G., Schumacher, T. N., Kagan, J. C., Fritsch, E. F., & Wu, C. J. (2026) · Nature Medicine · doi:10.1038/s41591-026-04241-9 · Cited by 30
Adjuvant systemic therapy in high-risk melanoma
Blankenstein, S. A., & van Akkooi, A. C. J. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000604 · Cited by 23
Satzger, I., Leiter, U., Gräger, N., Keim, U., Garbe, C., & Gutzmer, R. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.004 · Cited by 23
Romo1 is involved in the immune response of glioblastoma by regulating the function of macrophages
Sun, G., Cao, Y., Qian, C., Wan, Z., Zhu, J., Guo, J., & Shi, L. (2020) · Aging · doi:10.18632/aging.102648 · Cited by 26
Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors
Gonzalez, B. D., Eisel, S. L., Bowles, K. E., Hoogland, A. I., James, B. W., Small, B. J., Sharpe, S., Hyland, K. A., Bulls, H. W., Christy, S. M., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab171 · Cited by 25
Su, Y., Li, C.-C., Lin, Y., & Hsu, C. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730949 · Cited by 24
Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma
Gouda, M. A., Polívka, J., Huang, H. J., Treskova, I., Pivovarčíková, K., Fikrle, T., Woznica, V., Dustin, D. J., Call, S. G., Meric‐Bernstam, F., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100357 · Cited by 24
Eckardt, J., Schroeder, C., Martus, P., Armeanu–Ebinger, S., Kelemen, O., Gschwind, A., Bonzheim, I., Eigentler, T., Amaral, T. M. S., Ossowski, S., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03939-w · Cited by 22
Xiang, Z., Li, J., Zhang, Z., Cen, C., Chen, W., Jiang, B., Meng, Y., Wang, Y., Berglund, B., Zhai, G., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.883655 · Cited by 24
Stadler, J.-C., Keller, L., Meß, C., Bauer, A. T., Kött, J., Geidel, G., Heidrich, I., Vidal‐y‐Sy, S., Andreas, A., Stramaglia, C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006456 · Cited by 24
Augustin, R. C., Huang, Z., Ding, F., Zhai, S., McArdle, J., Santisi, A., Davis, M., Sander, C., Davar, D., Kirkwood, J. M., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1075823 · Cited by 25
Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma
Hoeijmakers, L. L., Reijers, I. L. M., & Blank, C. U. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0352 · Cited by 28
A twenty year perspective on melanoma therapy
Flaherty, K. T. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13125 · Cited by 23
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
Mandalà, M., Ferrari, A., Brecht, I. B., Suijkerbuijk, K. P. M., Maschke, L., Giannarelli, D., Indini, A., Ubaldi, M., Pecci, G., Atkinson, V. G., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114305 · Cited by 23
Self-citationGartrell, R. D., Marks, D. K., Rizk, E. M., Bogardus, M. H., Gerard, C. L., Barker, L. W., Fu, Y., Esancy, C. L., Li, G., Ji, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2847 · Cited by 24
Current Immunotherapy Practices in Melanoma
Rothermel, L. D., Sarnaik, A. A., Khushalani, N. I., & Sondak, V. K. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.001 · Cited by 23
Yu, Y., Tse, K. Y., Lee, H. H. Y., Chow, K.-L., Tsang, H.-W., Wong, R. W.-C., Cheung, E. T.-Y., Cheuk, W., Lee, V. W. K., Chan, W., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0345-2 · Cited by 23
Hepatic sinusoidal obstruction syndrome induced by nivolumab in advanced melanoma: a case report
Charvet, E., Lheure, C., Isnard, C., Franck, N., Kramkimel, N., Vallet‐Pichard, A., Dohan, A. J. J., Terris, B., Aractingi, S., Dupin, N., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.004 · Cited by 23
Melanoma Radiological Surveillance: A Review of Current Evidence and Clinical Challenges.
Howard, M. D. (2020) · PubMed Central · Cited by 27
Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy
Gutiontov, S. I., Pitroda, S. P., Chmura, S. J., Arina, A., & Weichselbaum, R. R. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.12.033 · Cited by 23
Cutaneous melanoma: cost of illness under Brazilian health system perspectives
da Veiga, C. R. P., da Veiga, C. P., Souza, A., Wainstein, A. J. A., de Melo, A. C., & Drummond‐Lage, A. P. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06246-1 · Cited by 24
“Anti-PD-1 treatments were not considered in the disease model’s adjuvant treatment options because to date there is no available information on overall survival [26, 27].”
BackgroundLooking into a Better Future: Novel Therapies for Metastatic Melanoma
Villani, A., Scalvenzi, M., Fabbrocini, G., Ocampo-Candiani, J., & Ocampo‐Garza, S. S. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00525-9 · Cited by 25
“A double-blind, randomized, controlled phase 3 adjuvant trial for patients with resected stage IIIB, IIIC, or IV melanoma was conducted in 2017 (CheckMate 238) [9].”
BackgroundMethodDahl, O., & Brydøy, M. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1555375 · Cited by 24
“In two randomized studies including resected malignant melanoma stage III or IV comparing pembrolizumab versus placebo and nivolumab versus ipilimumab, early results show best durable effect of the of pembrolizumab and nivolumab arms compared to the control groups with placebo and ipilimumab, respectively (difference…”
BackgroundQiu, J., Lin, H., Ke, D., Yu, Y., Xu, J., Qiu, H., Zheng, Q., Li, H., Zheng, H., Liu, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1066255 · Cited by 25
Bioactive metallic nanoparticles for synergistic cancer immunotherapy
Wang, L., Lin, D., Li, M., Yu, J., Yang, Y., Wang, H., Chu, H., Ye, J., & Liu, Y. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.02.022 · Cited by 25
“Furthermore, several immunotherapies have been approved by the US Food and Drug Administration (FDA) for their clinical efficacy.”
InfluentialRational combination of cancer immunotherapy in melanoma
Mandalà, M., & Rutkowski, P. L. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2506-y · Cited by 23
Self-citationComparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage
Teterycz, P., Lugowska, I. A., Koseła-Paterczyk, H., & Rutkowski, P. L. (2019) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1669-6 · Cited by 22
“, locoregional) may further improve the outcomes of the patients [4, 5].”
Self-citation
Metadata
- Authors
- Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J.-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N., Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., de Pril, V., Sabater, J., Qureshi, A., Larkin, J., & Ascierto, P. A.
- Affiliations
- University of Siena (IT)
- ORCID
- Weber, Jeffrey
- Gogas, Helen J.
- Arance, Ana M.
- Cowey, C. Lance
- Dalle, Stéphane
- Schenker, Michael
- Grob, Jean-Jacques
- Butler, Marcus O.
- Middleton, Mark R.
- Maio, Michele
- Atkinson, Victoria
- Queirolo, Paola
- Gonzalez, Rene
- Kudchadkar, Ragini R.
- Smylie, Michael
- Mortier, Laurent
- Atkins, Michael B.
- Long, Georgina V.
- Bhatia, Shailender
- Rutkowski, Piotr
- Yokota, Kenji
- Yamazaki, Naoya
- Sabater, Javier
- Larkin, James
- Ascierto, Paolo A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-09
- Volume
- 377
- Issue
- 19
- Pages
- 1824-1835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752227448
- Cited by
- 2,246
- References
- 19
- Citations by year
- 2026: 105 · 2025: 155 · 2024: 218 · 2023: 228 · 2022: 265 · 2021: 339 · 2020: 347 · 2019: 315 · 2018: 245 · 2017: 24
- FWCI
- 112.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Cancer Research UK (18892, 15951, 20613, 22795)
- Medical Research Council (MR/P024351/1)
- Japan Society for the Promotion of Science (16K10165)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, adjuvant therapy, advanced melanoma, immune checkpoint inhibitors, recurrence-free survival, PD-1 inhibitors, CTLA-4 inhibitors, R0 resection, treatment-related adverse events, melanoma recurrence, overall survival, progression-free survival
- MeSH terms
- Ipilimumab, Nivolumab, Cutaneous Malignant Melanoma, Adjuvants, Immunologic, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Disease-Free Survival, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.